Investing
US FDA panel votes against Merck’s chronic cough drug
© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
(Reuters) – The U.S. health regulator’s advisers on Friday did not recommend Merck’s drug for the treatment of chronic cough.
The FDA panel voted 12 to 1 that the data presented does not demonstrate substantial evidence of effectiveness of the oral tablet, gefapixant, for the treatment of refractory or unexplained chronic cough.
Read the full article here
-
Passive Income6 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles6 days ago
How Your Body Language Can Help Win a Disagreement
-
Side Hustles5 days ago
How to Be Unapologetically You and Why It Matters
-
Investing6 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles6 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles4 days ago
Mark Zuckerberg Is Now Second Richest Person in the World
-
Investing4 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles5 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool